Overview Dividends

(BIOA) BioAge Labs - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09077V1008

Azelaprag, BGE-102, Obesity, Neuroinflammation, NLRP3

Pharmaceuticals
Market Cap in USD: 460m

IPO / Inception: 2024-09-26
Return 12m vs S&P 500: 143%

EPS (Earnings per Share)

EPS CAGR: 0.52%
EPS Trend: 43.2%

Last SUE: -0.02
Qual. Beats: 0

Revenue

Rev. CAGR: 146.25%
Rev. Trend: 77.9%

Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	172%
Value at Risk 5%th	259%
Relative Tail Risk	-8.32%

Reward TTM
Sharpe Ratio	1.69
Alpha	162.24
CAGR/Max DD	-0.14

Character TTM
Hurst Exponent	0.402
Beta	0.690
Beta Downside	0.257

Drawdowns 3y
Max DD	88.23%
Mean DD	67.85%
Median DD	81.42%

Description: BIOA BioAge Labs December 25, 2025

BioAge Labs, Inc. (NASDAQ:BIOA) is a U.S.-based biopharmaceutical firm focused on developing therapeutics for metabolic diseases by leveraging a proprietary platform that integrates human aging datasets to pinpoint molecular targets linked to age-related decline.

The company’s lead asset, azelaprag, is an oral small-molecule currently in a Phase 1 trial for obesity and has entered a Phase 2 study in combination with tirzepatide targeting older adults-a demographic with rising obesity prevalence. A second program, BGE-102, is a brain-penetrant NLRP3 antagonist aimed at neuroinflammatory conditions, reflecting BioAge’s broader ambition to address age-driven pathologies.

As of the latest filing (Q3 2024), BioAge reported a market capitalization of roughly $210 million, cash and equivalents of $85 million, and a runway of about 12 months at current burn rates. The global obesity treatment market is estimated at >$200 billion and is expanding at ~8% CAGR, while the neuroinflammation space is attracting heightened R&D spending, suggesting a favorable macro backdrop but also intense competition from established players such as Novo Nordisk and Eli Lilly.

For a deeper, data-driven view of BIOA’s valuation and risk profile, consider checking ValueRay’s analyst tools.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-75.8m TTM) > 0 and > 6% of Revenue (6% = 355.0k TTM)

FCFTA -0.19 (>2.0%) and ΔFCFTA -3.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.19 (>3.0%) and CFO -58.5m > Net Income -75.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 11.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (35.9m) change vs 12m ago 925.9% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 1.84% (prev 0.0%; Δ 1.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -81.02 (EBITDA TTM -74.7m / Interest Expense TTM 924.0k) >= 6 (WARN >= 3)

Altman Z'' -10.80

(A) 0.87 = (Total Current Assets 290.8m - Total Current Liabilities 24.5m) / Total Assets 305.1m

(B) -1.01 = Retained Earnings (Balance) -307.5m / Total Assets 305.1m

warn (B) unusual magnitude: -1.01 — check mapping/units

(D) -11.12 = Book Value of Equity -307.2m / Total Liabilities 27.6m

Total Rating: -10.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.55

1. Piotroski 0.0pt

2. FCF Yield -32.61%

3. FCF Margin data missing

4. Debt/Equity 0.03

5. Debt/Ebitda 2.79

7. RoE -25.09%

8. Rev. Trend 77.91%

9. EPS Trend 43.16%

What is the price of BIOA shares?

As of January 07, 2026, the stock is trading at USD 15.41 with a total of 2,362,849 shares traded.
Over the past week, the price has changed by +13.06%, over one month by +30.26%, over three months by +173.71% and over the past year by +185.90%.

Is BIOA a buy, sell or hold?

BioAge Labs has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell BIOA.

Strong Buy: 0
Buy: 0
Hold: 3
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the BIOA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	12	-22.1%
Analysts Target Price	12	-22.1%
ValueRay Target Price	16.4	6.4%

BIOA Fundamental Data Overview January 04, 2026

Market Cap USD = 460.0m (460.0m USD * 1.0 USD.USD)
P/E Trailing = 0.9427
P/S = 77.7455
P/B = 1.7096
Beta = None
Revenue TTM = 5.92m USD
EBIT TTM = -74.9m USD
EBITDA TTM = -74.7m USD
Long Term Debt = 2.50m USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.71m USD (from shortTermDebt, last quarter)
Debt = 7.13m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -208.4m USD (from netDebt column, last quarter)
Enterprise Value = 181.4m USD (460.0m + Debt 7.13m - CCE 285.8m)
Interest Coverage Ratio = -81.02 (Ebit TTM -74.9m / Interest Expense TTM 924.0k)
FCF Yield = -32.61% (FCF TTM -59.1m / Enterprise Value 181.4m)
FCF Margin = -999.6% (FCF TTM -59.1m / Revenue TTM 5.92m)
Net Margin = -1281 % (Net Income TTM -75.8m / Revenue TTM 5.92m)
Gross Margin = 99.02% ((Revenue TTM 5.92m - Cost of Revenue TTM 58.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 97.60%)
Tobins Q-Ratio = 0.59 (Enterprise Value 181.4m / Total Assets 305.1m)
Interest Expense / Debt = 2.09% (Interest Expense 149.0k / Debt 7.13m)
Taxrate = 100.0% (out of range, set to none) (-71.1m / -71.1m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 11.87 (Total Current Assets 290.8m / Total Current Liabilities 24.5m)
Debt / Equity = 0.03 (Debt 7.13m / totalStockholderEquity, last quarter 277.5m)
Debt / EBITDA = 2.79 (negative EBITDA) (Net Debt -208.4m / EBITDA -74.7m)
Debt / FCF = 3.52 (negative FCF - burning cash) (Net Debt -208.4m / FCF TTM -59.1m)
Total Stockholder Equity = 302.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.84% (Net Income -75.8m / Total Assets 305.1m)
RoE = -25.09% (Net Income TTM -75.8m / Total Stockholder Equity 302.1m)
RoCE = -24.58% (EBIT -74.9m / Capital Employed (Equity 302.1m + L.T.Debt 2.50m))
RoIC = 1445 % (out of range, set to none) (EBIT -74.9m / (Assets 305.1m - Curr.Liab 24.5m - Cash 285.8m))
WACC = 8.43% (E(460.0m)/V(467.2m) * Re(8.56%) + (debt cost/tax rate unavailable))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 450.0%
Fair Price DCF = unknown (Cash Flow -59.1m)
EPS Correlation: 43.16 | EPS CAGR: 0.52% | SUE: -0.02 | # QB: 0
Revenue Correlation: 77.91 | Revenue CAGR: 146.3% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.65 | Chg30d=-0.119 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.79 | Chg30d=-0.408 | Revisions Net=+0 | Growth EPS=-28.2% | Growth Revenue=-49.0%

Additional Sources for BIOA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle